[Polyhydramnios, prematurity, dystrophy, polyuria, constipation, nephrocalcinosis and renal tumor: presentation of a classic tubulopathy].
BACKGROUND
A diagnostic workup of a renal mass will rarely lead to the diagnosis of a tubulopathy. We would like to stress the importance of taking a detailed history and of evaluating these findings in the context of the clinical symptoms.


METHODS
A 3 year old boy with a renal mass, diagnosed due to urinary tract infection, was referred to exclude renal malignancy. Detailed history revealed polyuria and polydipsia in a child with preterm delivery due to polyhydramnios. These symptoms, together with poor thriving are highly suggestive of a neonatal form of Bartter syndrome. This diagnosis was substantiated by ultrasound findings of nephrocalcinosis and urolithiasis due to hypercalciuria and a renal abscess. Detection of mutations in the KCNJ1-gene confirmed the diagnosis. After unilateral nephrectomy for acute destructive nephritis and under medication with indomethacin and potassium citrate the patient is now thriving well.


CONCLUSIONS
Renal masses suspicious of malignancy may distract from a hereditary tubulopathy. Typical clinical history and presentation with prematurity, polyhydramnios, polyuria, poor thriving and urolithiasis requires diagnostic evaluation of tubular function since routine laboratory tests and urinary dip stick may be normal. Unrecognized, neonatal Bartter syndrome may lead to severe complications including loss of kidney function.
Schnakenburg
C von
Cv
Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Germany. christian.schnakenburg@uniklinik-freiburg.de
Frankenschmidt
A
A
Neumann
J
J
Häffner
K
K
Jeck
N
N
Pohl
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D001477:Bartter Syndrome / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D019355:Calcium Citrate / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D003248:Constipation / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D005503:Food Additives / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D009392:Nephrectomy; D009397:Nephrocalcinosis / Q000150:complications; D006831:Polyhydramnios; D011141:Polyuria / Q000209:etiology; D011247:Pregnancy; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D014552:Urinary Tract Infections / Q000517:prevention & control; D052878:Urolithiasis / Q000209:etiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005503:Food Additives; D019355:Calcium Citrate; D007213:Indomethacin